,0
0,Eli Lilly Sparks As Rival Novo Says Diabetes Drug Could Treat Kidney Disease — But Is Lilly Stock A Buy?
1,Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement
2,RPT-FOCUS-Demand for weight-loss drugs fuels global rise in counterfeits
3,Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer
4,Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years
5,Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg
6,Eli Lilly Sparks As Rival Novo Says Diabetes Drug Could Treat Kidney Disease — But Is Lilly Stock A Buy?Investor's Business Daily
7,Factbox-Corporate America weighs risks of the Ozempic effectReuters
8,Ozempic Boom Is an Opportunity for Health Insurers
9,FOCUS-Demand for weight-loss drugs fuels global rise in counterfeits
10,The Next Hot Obesity Drug Won’t Be Approved for Years. Online Sellers Hawk It Anyway.
11,Is Eli Lilly and Company (LLY) Well Positioned in the Market?
